Dose-dependent decreases in targeted fatty acids were seen with YTX-7739, an investigational therapy for Parkinson’s disease, suggesting the medicine engages its therapeutic target, according to the results of a Phase 1a multiple-ascending dose study in healthy volunteers.
The nonprofit Parkinson Canada has teamed up with technology company Catalyst to enhance awareness of available digital health tools that can help people with Parkinson’s disease keep up their medication regimen. People diagnosed with Parkinson’s usually require treatment with multiple medications, often with frequent dosing, to adequately…
Double vision (diplopia) is common in people with Parkinson’s — affecting up to an estimated 30% of patients — and is linked to both motor and non‐motor disease symptoms, a new large-scale, longitudinal study has found. Parkinson’s patients with double vision were more likely to be older, non-white, female,…
A television producer, legislators, and movement disorder specialists are among recent recipients of The Michael J. Fox Foundation’s (MJFF) 2020 Parkinson’s Advocacy Awards. The annual presentation, which this year took place virtually at the organization’s Parkinson’s Policy Forum, recognizes individuals or groups that do outstanding work advocating on behalf…
PharmaTher is seeking regulatory approval to launch a clinical trial of the painkiller ketamine for levodopa-induced dyskinesia — the uncontrolled, involuntary movements that affect as many as 80% of Parkinson’s patients following treatment. The company, which focuses on the research and development of psychedelic pharmaceuticals, has submitted an…
The personality trait neuroticism correlates with a higher risk of developing Parkinson’s disease, according to recent research. The study, “Neuroticism and Risk of Parkinson’s Disease: A Meta-Analysis,” was published in the journal Movement Disorders. Neuroticism refers to an individual’s tendency to experience negative emotions, self-consciousness, vulnerability…
Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. UCB’s experimental oral therapy UCB0599 was generally well tolerated in people with mild to moderate Parkinson’s disease…
A newly opened Phase 2 clinical trial is evaluating adult stem cells as a potentially disease-modifying treatment for Parkinson’s, building on an earlier study, thought to be the first of its kind, that found a single infusion of these cells safe and well tolerated by patients. This study will use…
Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Long-term treatment with Duodopa (levodopa-carbidopa intestinal gel) safely and effectively lessens motor and non-motor symptoms and improves quality of life…
Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. In two clinical studies, Kynmobi (apomorphine hydrochloride) was associated with greater and faster motor improvement than was levodopa among…
Get regular updates to your inbox.
